Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Philippe Bernard

Showing results (121-130 of 135) with videos related to

Pageof 14
Sort By:
American Journal of Clinical Pathology|June 29, 2005
Blastic NK-cell lymphomas (agranular CD4+CD56+ hematodermic neoplasms): a reviewTony Petrella, Martine Bagot, Rein Willemze, et al.
Journal of Advanced Research|May 17, 2022
Characterization of the skin microbiota in bullous pemphigoid patients and controls reveals novel microbial indicators of diseaseMeriem Belheouane, Britt M Hermes, Nina Van Beek, et al.
The Journal of Investigative Dermatology|January 30, 2009
A comparison of two regimens of topical corticosteroids in the treatment of patients with bullous pemphigoid: a multicenter randomized studyPascal Joly, Jean-Claude Roujeau, Jacques Benichou, et al.
Science Translational Medicine|March 8, 2013
Long-term remissions of severe pemphigus after rituximab therapy are associated with prolonged failure of desmoglein B cell responseNatacha Colliou, Damien Picard, Frédérique Caillot, et al.
European Journal of Cancer (Oxford, England : 1990)|March 10, 2026
Cemiplimab versus historical systemic treatments for locally advanced or metastatic cutaneous squamous cell carcinomas: Results from the French study TOSCACaroline Robert, Emilie Gérard, Emilie Lanoy, et al.
The Journal of Investigative Dermatology|April 10, 2017
Meeting Report of the Pathogenesis of Pemphigus and Pemphigoid Meeting in Munich, September 2016Enno Schmidt, Volker Spindler, Rüdiger Eming, et al.
The Journal of Investigative Dermatology|December 14, 2018
Higher Frequency of Dipeptidyl Peptidase-4 Inhibitor Intake in Bullous Pemphigoid Patients than in the French General PopulationMarthe Plaquevent, Florence Tétart, Laurence Fardet, et al.
The British Journal of Dermatology|March 10, 2026
Combined methotrexate and short-term superpotent topical corticosteroids compared with prolonged superpotent topical corticosteroids alone in bullous pemphigoid: a multicentre, noninferiority randomised clinical trialOlivier Dereure, Philippe Bernard, Olivier Chosidow, et al.
Lancet (London, England)|March 27, 2017
First-line rituximab combined with short-term prednisone versus prednisone alone for the treatment of pemphigus (Ritux 3): a prospective, multicentre, parallel-group, open-label randomised trialPascal Joly, Maud Maho-Vaillant, Catherine Prost-Squarcioni, et al.
JAMA Dermatology|January 24, 2024
Sustained Remission Without Corticosteroids Among Patients With Pemphigus Who Had Rituximab as First-Line Therapy: Follow-Up of the Ritux 3 TrialBillal Tedbirt, Maud Maho-Vaillant, Estelle Houivet, et al.
Pageof 14

Showing results (121-130 of 135) with videos related to

Sort By:
Pageof 14
American Journal of Clinical Pathology|June 29, 2005
Blastic NK-cell lymphomas (agranular CD4+CD56+ hematodermic neoplasms): a reviewTony Petrella, Martine Bagot, Rein Willemze, et al.
Journal of Advanced Research|May 17, 2022
Characterization of the skin microbiota in bullous pemphigoid patients and controls reveals novel microbial indicators of diseaseMeriem Belheouane, Britt M Hermes, Nina Van Beek, et al.
The Journal of Investigative Dermatology|January 30, 2009
A comparison of two regimens of topical corticosteroids in the treatment of patients with bullous pemphigoid: a multicenter randomized studyPascal Joly, Jean-Claude Roujeau, Jacques Benichou, et al.
Science Translational Medicine|March 8, 2013
Long-term remissions of severe pemphigus after rituximab therapy are associated with prolonged failure of desmoglein B cell responseNatacha Colliou, Damien Picard, Frédérique Caillot, et al.
European Journal of Cancer (Oxford, England : 1990)|March 10, 2026
Cemiplimab versus historical systemic treatments for locally advanced or metastatic cutaneous squamous cell carcinomas: Results from the French study TOSCACaroline Robert, Emilie Gérard, Emilie Lanoy, et al.
The Journal of Investigative Dermatology|April 10, 2017
Meeting Report of the Pathogenesis of Pemphigus and Pemphigoid Meeting in Munich, September 2016Enno Schmidt, Volker Spindler, Rüdiger Eming, et al.
The Journal of Investigative Dermatology|December 14, 2018
Higher Frequency of Dipeptidyl Peptidase-4 Inhibitor Intake in Bullous Pemphigoid Patients than in the French General PopulationMarthe Plaquevent, Florence Tétart, Laurence Fardet, et al.
The British Journal of Dermatology|March 10, 2026
Combined methotrexate and short-term superpotent topical corticosteroids compared with prolonged superpotent topical corticosteroids alone in bullous pemphigoid: a multicentre, noninferiority randomised clinical trialOlivier Dereure, Philippe Bernard, Olivier Chosidow, et al.
Lancet (London, England)|March 27, 2017
First-line rituximab combined with short-term prednisone versus prednisone alone for the treatment of pemphigus (Ritux 3): a prospective, multicentre, parallel-group, open-label randomised trialPascal Joly, Maud Maho-Vaillant, Catherine Prost-Squarcioni, et al.
JAMA Dermatology|January 24, 2024
Sustained Remission Without Corticosteroids Among Patients With Pemphigus Who Had Rituximab as First-Line Therapy: Follow-Up of the Ritux 3 TrialBillal Tedbirt, Maud Maho-Vaillant, Estelle Houivet, et al.
Pageof 14